JPMorgan Chase & Co. Issues Positive Forecast for Johnson & Johnson (NYSE:JNJ) Stock Price

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan raised its Johnson & Johnson price target from $285 to $300, implying about 11% upside, but maintained a neutral rating.
  • Analyst sentiment overall is more positive: the stock carries a consensus “Moderate Buy” rating and an average price target of $276.54.
  • J&J beat quarterly earnings and revenue estimates, with EPS of $2.59 and revenue of $25.40 billion; revenue increased 5.9% year over year.
  • Five stocks to consider instead of Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ - Get Free Report) had its price objective lifted by equities research analysts at JPMorgan Chase & Co. from $285.00 to $300.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 10.97% from the stock's current price.

Several other research firms have also recently issued reports on JNJ. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. Sanford C. Bernstein set a $270.00 price target on shares of Johnson & Johnson in a research report on Thursday, October 15th. Leerink Partners decreased their price objective on Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating for the company in a research report on Wednesday, October 14th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating on the stock in a report on Thursday, October 15th. Finally, UBS Group set a $270.00 price objective on Johnson & Johnson in a report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $276.54.

View Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Stock Up 1.2%

Shares of NYSE JNJ traded up $3.21 during midday trading on Friday, hitting $270.35. The company's stock had a trading volume of 3,563,820 shares, compared to its average volume of 7,945,597. The firm has a market capitalization of $650.82 billion, a price-to-earnings ratio of 40.95, a price-to-earnings-growth ratio of 2.74 and a beta of 0.22. Johnson & Johnson has a 1 year low of $199.90 and a 1 year high of $290.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The business's fifty day simple moving average is $267.43 and its two-hundred day simple moving average is $250.79.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter last year, the company posted $2.80 EPS. The firm's revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the business's stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.16% of the company's stock.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently modified their holdings of JNJ. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $28,000. Matrix Trust Co lifted its position in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares during the period. Navigoe LLC boosted its position in shares of Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company's stock valued at $38,000 after purchasing an additional 55 shares in the last quarter. Montgomery Financial Services LLC acquired a new position in Johnson & Johnson in the second quarter worth approximately $43,000. Finally, Hanseatic Management Services Inc. acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth $52,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson News Roundup

These are some of the JNJ news items that stood out recently:

  • Positive Sentiment: J&J filed for FDA approval to expand CAPLYTA to bipolar I mania or mixed episodes, backed by two positive Phase 3 studies. Approval would add a potential indication and broaden the drug’s commercial opportunity. Article
  • Positive Sentiment: Recent coverage highlighted promising prostate-cancer data for J&J’s $3.05 billion Halda acquisition, suggesting a possible longer-term pipeline catalyst. Article
  • Negative Sentiment: ETFs were reported as net sellers of $144.2 million in J&J shares on Nov. 18, a potential near-term supply overhang; the report alone does not establish a lasting shift in investor sentiment. Article

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Recommended Stories

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines